WO2010092260A8 - Composition pharmaceutique solide contenant le 6-0x0-6,7,8, 9,10, ιl-hexahydrocyclohepta(c) chr0men-3-yl sulfamate et polymorphes de ce dernier - Google Patents

Composition pharmaceutique solide contenant le 6-0x0-6,7,8, 9,10, ιl-hexahydrocyclohepta(c) chr0men-3-yl sulfamate et polymorphes de ce dernier Download PDF

Info

Publication number
WO2010092260A8
WO2010092260A8 PCT/FR2010/000117 FR2010000117W WO2010092260A8 WO 2010092260 A8 WO2010092260 A8 WO 2010092260A8 FR 2010000117 W FR2010000117 W FR 2010000117W WO 2010092260 A8 WO2010092260 A8 WO 2010092260A8
Authority
WO
WIPO (PCT)
Prior art keywords
hexahydrocyclohepta
chromen
oxo
sulfamate
polymorphs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2010/000117
Other languages
English (en)
Other versions
WO2010092260A2 (fr
WO2010092260A3 (fr
Inventor
Nathalie Mondoly
Bertrand Poirot
Anne Brochard
Joël Richard
Delphine Delahaye
Christian Diolez
Alain Rolland
Francis Diancourt
Gérard Coquerel
Damien Martins
Julie Linol
Ophélie HOUSSIN
Marie-Noêlle PETIT
Barry Victor Lloyd Potter
Lok Wai Lawrence Woo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Ipsen Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0900656A external-priority patent/FR2942226B1/fr
Priority claimed from FR0900655A external-priority patent/FR2942225B1/fr
Priority to UAA201110940A priority Critical patent/UA104753C2/ru
Priority to RU2011137516/04A priority patent/RU2011137516A/ru
Priority to AU2010212753A priority patent/AU2010212753A1/en
Priority to BRPI1008422A priority patent/BRPI1008422A2/pt
Priority to MX2011008239A priority patent/MX2011008239A/es
Priority to CA2751393A priority patent/CA2751393A1/fr
Application filed by Ipsen Pharma SAS filed Critical Ipsen Pharma SAS
Priority to EP10707096A priority patent/EP2396311A2/fr
Priority to JP2011549626A priority patent/JP2012517988A/ja
Priority to CN2010800077893A priority patent/CN102317276A/zh
Publication of WO2010092260A2 publication Critical patent/WO2010092260A2/fr
Publication of WO2010092260A3 publication Critical patent/WO2010092260A3/fr
Publication of WO2010092260A8 publication Critical patent/WO2010092260A8/fr
Anticipated expiration legal-status Critical
Priority to US13/430,523 priority patent/US8691281B2/en
Priority to US13/957,067 priority patent/US20140056977A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)

Abstract

La présente invention se rapporte à une composition pharmaceutique solide comprenant le principe actif 6-oxo-6,7,8,9, 10, 11-hexahydrocyclohepta[c]chromen-3-yl sulfamate. La présente invention concerne égalament des polymorphes du composé 6- oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate.
PCT/FR2010/000117 2009-02-13 2010-02-12 Compositions pharmaceutiques du 6-oxo-6.7.8,9.10.11-hexahydrocyclohepta mchromen-3-yl sulfamate Ceased WO2010092260A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP2011549626A JP2012517988A (ja) 2009-02-13 2010-02-12 ６−オキソ−６，７，８，９，１０，１１−ヘキサヒドロシクロヘプタ［ｃ］クロメン−３−イルスルファメート
RU2011137516/04A RU2011137516A (ru) 2009-02-13 2010-02-12 ТВЕРДАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ 6-ОКСО-6,7,8,9,10,11-ГЕКСАГИДРОЦИКЛОГЕПТА[c]ХРОМЕН-3-ИЛСУЛЬФАМАТ И ЕГО ПОЛИФОРМЫ
CN2010800077893A CN102317276A (zh) 2009-02-13 2010-02-12 包含氨基磺酸6-氧代-6，7，8，9，10，11-六氢环庚三烯并[c]色烯-3-基酯和其多晶型物的固体药物组合物
AU2010212753A AU2010212753A1 (en) 2009-02-13 2010-02-12 Solid pharmaceutical composition containing 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (c)chromen-3-yl sulfamate and polymorphs thereof
BRPI1008422A BRPI1008422A2 (pt) 2009-02-13 2010-02-12 composição farmacêutica sólida, processo de preparação de uma composição farmacêutica sólida, e, composto polimórfico
MX2011008239A MX2011008239A (es) 2009-02-13 2010-02-12 Composicion farmaceutica solida que contiene sulfamato de 6-oxo-6,7,8,9,10,11-hexahidrociclohepta[c]cromen-3-ilo y sus polimorfos.
CA2751393A CA2751393A1 (fr) 2009-02-13 2010-02-12 Compositions pharmaceutiques du 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta [c]chromen-3-yl sulfamate
UAA201110940A UA104753C2 (en) 2009-02-13 2010-02-12 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta[c]chromen-3-yl sulfamate and polymorph
EP10707096A EP2396311A2 (fr) 2009-02-13 2010-02-12 Composition pharmaceutique solide contenant le 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta(c)chromen-3-yl sulfamate et polymorphes de ce dernier
US13/430,523 US8691281B2 (en) 2009-02-13 2012-03-26 Solid pharmaceutical composition containing 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (C)chromen-3-yl sulfamate and polymorphs thereof
US13/957,067 US20140056977A1 (en) 2009-02-13 2013-08-01 Solid pharmaceutical composition containing 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (c)chromen-3-yl sulfamate and polymorphs thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0900655 2009-02-13
FR0900656A FR2942226B1 (fr) 2009-02-13 2009-02-13 Nouveau polymorphe cristallin du 6-oxo+6,7,8,9,10,11-hexahydrocyclohepta°c!chromen-3-yl sulfamate
FR0900656 2009-02-13
FR0900655A FR2942225B1 (fr) 2009-02-13 2009-02-13 Variete i du 6-oxo-6,7,8,9,10,11-hexahydroclyclohepta5°c!chromen-3 yl sulfamate de granulometrie reduite

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13201614 A-371-Of-International 2010-02-12
US13/430,523 Continuation US8691281B2 (en) 2009-02-13 2012-03-26 Solid pharmaceutical composition containing 6-oxo-6,7,8,9,10,11-hexahydrocyclohepta (C)chromen-3-yl sulfamate and polymorphs thereof

Publications (3)

Publication Number Publication Date
WO2010092260A2 WO2010092260A2 (fr) 2010-08-19
WO2010092260A3 WO2010092260A3 (fr) 2011-02-17
WO2010092260A8 true WO2010092260A8 (fr) 2011-08-11

Family

ID=42562120

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2010/000117 Ceased WO2010092260A2 (fr) 2009-02-13 2010-02-12 Compositions pharmaceutiques du 6-oxo-6.7.8,9.10.11-hexahydrocyclohepta mchromen-3-yl sulfamate

Country Status (10)

Country Link
EP (1) EP2396311A2 (fr)
JP (1) JP2012517988A (fr)
KR (1) KR20110115607A (fr)
CN (1) CN102317276A (fr)
AU (1) AU2010212753A1 (fr)
BR (1) BRPI1008422A2 (fr)
CA (1) CA2751393A1 (fr)
MX (1) MX2011008239A (fr)
RU (1) RU2011137516A (fr)
WO (1) WO2010092260A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110520110A (zh) * 2017-03-08 2019-11-29 阿瑞雅德制药公司 包含5-氯-n4-[2-(二甲基磷酰基)苯基]-n2-{2-甲氧基-4-[4-(4-甲基哌嗪-1-基)哌啶-1-基]苯基}嘧啶-2,4-二胺的药物制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9603325D0 (en) * 1996-02-16 1996-04-17 Imperial College A compound
US6921776B1 (en) * 1996-02-16 2005-07-26 Sterix Limited Compound
CN1309387C (zh) * 2003-04-15 2007-04-11 南昌弘益科技有限公司 溶出度得到提高的甲芬那酸分散片及其制备方法—镇痛、解热、抗炎药
GB0408308D0 (en) * 2004-04-14 2004-05-19 Vectura Ltd Pharmaceutical compositions
GB0511190D0 (en) * 2005-06-01 2005-07-06 Sterix Ltd Use
WO2008066899A2 (fr) * 2006-11-28 2008-06-05 Marinus Pharmaceuticals Formulations de nanoparticules et procédés de préparation et d'utilisation de celles-ci

Also Published As

Publication number Publication date
CA2751393A1 (fr) 2010-08-19
BRPI1008422A2 (pt) 2016-03-01
KR20110115607A (ko) 2011-10-21
WO2010092260A2 (fr) 2010-08-19
AU2010212753A1 (en) 2011-09-01
EP2396311A2 (fr) 2011-12-21
JP2012517988A (ja) 2012-08-09
RU2011137516A (ru) 2013-03-20
CN102317276A (zh) 2012-01-11
MX2011008239A (es) 2011-09-06
WO2010092260A3 (fr) 2011-02-17

Similar Documents

Publication Publication Date Title
WO2009111653A3 (fr) Agents thérapeutiques antiviraux
WO2011012816A3 (fr) Formulation pharmaceutique
WO2007090393A3 (fr) Préparation pharmaceutique
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
WO2011077043A3 (fr) Derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
WO2009005677A3 (fr) Composés antiviraux
WO2009005676A3 (fr) Composés antiviraux
WO2011157722A3 (fr) Composition contenant de l'ivabradine solide
WO2008001195A3 (fr) Nouveaux procédés de synthèse d'inhibiteurs de dpp iv
WO2010049454A3 (fr) Composition antimicrobienne tirée de copépodes
TW200942524A (en) Novel aminomethyl benzene derivatives
WO2010139981A3 (fr) Procédés d'élaboration de formes cristallines
WO2011009938A3 (fr) Stambomycine et dérivés, leur production et leur utilisation comme médicaments
WO2010049449A3 (fr) Nouveaux sels de sunitinib
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
WO2009115084A3 (fr) Nouveaux dérivés de pyrrolopyrimidine et leurs utilisations
WO2007068894A3 (fr) Nouveaux composes
WO2008021346A3 (fr) Palipéridone pure et ses procédés d'obtention
WO2009062659A3 (fr) Polymorphes d'erdostéine énantiopure
WO2010079045A3 (fr) Nouveaux sels
WO2008081268A3 (fr) Compositions pharmaceutiques d'entacapone
WO2010119450A3 (fr) Procédé amélioré pour la préparation de la desmopressine ou de ses sels pharmaceutiquement acceptables
WO2011067236A3 (fr) Polymorphes de raltegravir
WO2010061220A3 (fr) Nouveaux procédés et polymorphes purs
WO2009034432A8 (fr) Nouveaux composés actifs utilisés comme antagonistes des récepteurs muscariniques

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080007789.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10707096

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2751393

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/008239

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011549626

Country of ref document: JP

Ref document number: 2010212753

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2010212753

Country of ref document: AU

Date of ref document: 20100212

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 6823/DELNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20117021103

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: a201110940

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 2011137516

Country of ref document: RU

Ref document number: 2010707096

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1008422

Country of ref document: BR

ENP Entry into the national phase

Ref document number: PI1008422

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110811